alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I

106TH CONGRESS

2D SESSION H. R. 5444

To amend the Internal Revenue Code of 1986 to provide for capital gains

treatment for certain termination payments received by former insurance

salesmen.

IN THE HOUSE OF REPRESENTATIVES

OCTOBER 11, 2000

Mr. SAM JOHNSON of Texas introduced the following bill; which was referred

to the Committee on Ways and Means

A BILL

To amend the Internal Revenue Code of 1986 to provide

for capital gains treatment for certain termination payments received by former insurance salesmen.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘Fair Tax Treatment

5 for Insurance Agents’ Termination Payments Act of

6 2000’’.
2

•HR 5444 IH

1 SEC. 2. CAPITAL GAINS TREATMENT OF QUALIFIED TERMI2 NATION PAYMENTS RECEIVED BY FORMER

3 INSURANCE SALESMEN.

4 (a) IN GENERAL.—Part IV of subchapter P of chap5 ter 1 of the Internal Revenue Code of 1986 is amended

6 by adding at the end the following new section:

7 ‘‘SEC. 1261. QUALIFIED TERMINATION PAYMENTS RE8 CEIVED BY FORMER INSURANCE SALESMEN.

9 ‘‘(a) GENERAL.—A qualified termination payment re10 ceived during the taxable year from an insurance company

11 by an individual in the capacity of a former insurance

12 salesman for such company shall be considered a sale or

13 exchange of a capital asset held for more than 12 months.

14 ‘‘(b) QUALIFIED TERMINATION PAYMENT.—For pur15 poses of this section, the term ‘qualified termination pay16 ment’ means any amount received by a former insurance

17 salesman if—

18 ‘‘(1) such amount is received after termination

19 of such individual’s agreement to perform services as

20 an insurance salesman for such company,

21 ‘‘(2) such individual performs no services for

22 such company after such termination and before the

23 close of such taxable year,

24 ‘‘(3) such individual enters into a covenant not

25 to compete against such company which applies to at
3

•HR 5444 IH

1 least the 1-year period beginning on the date of such

2 termination, and

3 ‘‘(4) the amount of such payment depends pri4 marily on policies sold by or credited to the account

5 of such individual or the extent to which such poli6 cies remain in force for some period after such ter7 mination, or both.’’.

8 (b) CLERICAL AMENDMENT.—The table of sections

9 for such part IV is amended by adding at the end the

10 following new item:

‘‘Sec. 1261. Qualified termination payments received by former

insurance salesmen.’’

11 (c) EFFECTIVE DATE.—The amendments made by

12 this section shall apply to taxable years ending after the

13 date of the enactment of this Act.

Æ
§ 102-33.335 What are the receiving agency's responsibilities in the transfer of aircraft parts? An agency that receives transferred aircraft parts must: ( a ) Verify that all applicable labels and tags and historical and modification records accompany all serviceable aircraft parts (*i.e.,* parts that are intended for flight use) that you receive. This requirement does not apply to parts for ground use only. See the tables in § 102-33.370.
( b ) Mutilate all transferred parts that you discover to be unsalvageable, and dispose of them properly, following the procedures in § 102-33.315.
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Injuries and Accident Causes in Fertilizer Manufacturing : a Detailed Analysis of Hazards and Injury-frequency Rates in 1946 by Region, Plant-Size, and Department

              																	McElroy, Frank S. (Frank Shafer)					 and 	McCormack, George R. (George Robertson). 						*Injuries and Accident Causes in Fertilizer Manufacturing : a Detailed Analysis of Hazards and Injury-frequency Rates in 1946 by Region, Plant-Size, and Department : Bulletin of the United States Bureau of Labor Statistics, No. 949*,												Washington, D.C: 								U.S. Govt. Print. Off., 										1949,									https://fraser.stlouisfed.org/title/4375,			accessed on September 19, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

LURENZO LEE WILLIAMS,

Plaintiff

- Appellant,

v.

G. KALISHER, Dr., Physician and Surgeon/CTF

- North Soledad State Prison; et al.,

Defendants

- Appellees. No. 17

- 16725

D.C. No. 5:15

- cv

- 03068

- NC

MEMORANDUM *

Appeal from the United States District Court

for the Northern District of California Nathanael M. Cousins, Magistrate Judge, Presiding **

Submitted April 11 , 2018 * * *

Before: SILVERMAN, PAEZ, and OWENS, Circuit Judges.

Lurenzo Lee Williams, a California state prisoner, appeals pro se from the

district court’s summary judgment in his 42 U.S.C. § 1983 action alleging

* This disposition is not appropriate for publication and is not pre cedent except as provided by Ninth Circuit Rule 36

- 3.

** The parties consented to proceed before a magistrate judge. See 28 U.S.C. § 636(c).

** * The panel unanimously concludes this case is suitable for decision without oral argument. See Fed. R. App. P. 34(a)(2). 

# FILED

APR 13 2018

MOLLY C. DWYER, CLER K

U.S. COURT OF APPEAL S2 17

- 16725

deliberate indifference to his serious medical needs. We have jurisdiction under 28

U.S .C. § 1291. We review de novo. Toguchi v. Chung , 391 F.3d 1051, 1056 (9th

Cir. 2004). We affirm.

The district court properly granted summary judgment because Williams

failed to raise a genuine dispute of material fact as to whether defendants were

deliberately indifferent in treating Williams’s pain or denying his request for an

MRI

. See id. at 1057

- 60 (deliberate indifference is a high legal standard; medical

malpractice, negligence, or a difference in medical opinion concerning the course

of treatment does not amount to deliberate indifference).

The district court did not abuse its discretion in per mitting defendants to file

a new motion for summary judgment to provide Rand notice in a separate

document

. See Hoffman v. Tonnemacher , 593 F.3d 908, 911

- 12 (9th Cir. 2010)

(standard of review ); see also Rand v. Roland , 154 F.3d 952, 960 (9th Cir. 1998)

( en banc) (“[T]he ultimate responsibility of assuring that the prisoner receives fair

notice remains with the district court.”).

The district court did not abuse its discretion by granting defendants’

requests for extensions of time to file a motion for sum mary judgment. See FTC v.

Gill , 265 F.3d 944, 957 (9th Cir. 2001) (district court has broad discretion to

control its docket).

We reject as without merit Williams’s contentions that defendant Kalisher3 17

- 16725

failed to file a timely motion for summary judgment, o r that she was required to

file a declaration in support of defendants’ motion.

AFFIRMED.
§ 404.1707 Appointing a representative. We will recognize a person as your representative if: ( a ) You and your representative complete and sign our prescribed appointment form; and
( b ) You or your representative file our prescribed appointment form in the manner we designate.
[89 FR 67554, Aug. 21, 2024]
EXHIBIT 10
                                                                      ----------



NORWEST
CORPORATION

135 East South Temple, 12th Floor
Salt Lake City, Utah  84111 USA
Tel (801) 539-0044
USA (800) 266-6351
Fax (801) 539-0055

Gary M. Stubblefield
Vice President


May 3, 2004

                                                                   File No. 2580

Sean Bovingdon
Controller
Western Oil Sands, Inc.
Suite 2400
Ernst & Young Tower
440 Second Avenue S.W.
Calgary, Alberta T2P 5E9
Canada


SUBJECT:  CONSENT LETTER

Dear Sean:

We hereby consent to references to our name and to the Reports in the Company's
Annual Report on Form 40-F to be filed with the United States Securities and
Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended.
We also confirm that we have read the Annual Information Form and that we have
no reason to believe that there are any misrepresentations in the information
contained in it that are derived from the Reports or that are within our
knowledge as a result of the services we performed in connection with the
Reports.


Sincerely,

NORWEST CORPORATION
(Formerly NorWest Mine Services, Inc.)


/s/ Gary M. Stubblefield
------------------------
Gary M. Stubblefield
Vice President
Exhibit 32.1




CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




The following certification accompanies the issuers
Annual Report on Form 10-KSB and is not filed, as provided in SEC Release Nos. 33-8238 and 34-47986 dated June 5, 2003.




In connection with the Annual Report of Eagle Bancorp (the
Company) on Form 10-KSB for the fiscal year ending June 30, 2006 as filed with the Securities and Exchange Commission on the date hereof
(the Report), we, Larry A. Dreyer, Chief Executive Officer of the Company, and Peter J. Johnson, Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigneds
knowledge:


|(1) |  | The Report fully complies with the requirements of section 13(a)
or 15(d) of the Securities Exchange Act of 1934, as amended; and
|--- |  | ---------------------------------------------------------------------------------------------------------------------------------

|(2) |  | The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the Company.
|--- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------



A signed original of this written statement required by
Section 906 will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


|/s/ Larry A. Dreyer                   |  |  |  | /s/ Peter J. Johnson                
|------------------------------------- |  |  |  | ------------------------------------
|Larry A.
Dreyer                       |  |  |  | Peter J. Johnson                    
|President and
Chief Executive Officer |  |  |  | Exec. VP and Chief Financial Officer
|September 15,
2006                    |  |  |  | September 15, 2006                  

---
```

[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5382 Introduced in House (IH)]

106th CONGRESS
  2d Session
                                H. R. 5382

 To allow the Secretary of Agriculture to use existing authorities to 
provide export promotion assistance for tobacco and tobacco products of 
                           the United States.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            October 4, 2000

 Mr. Fletcher (for himself, Mr. Ewing, Mr. Boucher, Mr. Whitfield, Mr. 
    Lewis of Kentucky, Mr. McIntyre, and Mr. Goode) introduced the 
   following bill; which was referred to the Committee on Agriculture

_______________________________________________________________________

                                 A BILL

 
 To allow the Secretary of Agriculture to use existing authorities to 
provide export promotion assistance for tobacco and tobacco products of 
                           the United States.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Tobacco Export Marketing Enhancement 
Act''.

SEC. 2. AGRICULTURAL EXPORT PROGRAM FOR TOBACCO.

    Notwithstanding any other provision of law, the Secretary of 
Agriculture may exercise the authorities of section 203 (relating to 
the market access program) and title VII (relating to the foreign 
market development cooperation program) of the Agricultural Trade Act 
of 1978 (7 U.S.C. 5623 and 5713 et seq.) to provide assistance for the 
development, maintenance, and expansion of foreign markets for tobacco 
and tobacco products of the United States.
                                 <all>
```
#### § 102-118.655 Are there time limits on a TSP request for an administrative review by the Civilian Board of Contract Appeals (CBCA)?

Yes, the CBCA must receive a request for review from the TSP within six months (not including times of war) from the date the settlement action was taken or within the periods of limitation specified in 31 U.S.C. 3726, as amended, whichever is later. Details regarding where and how to file are available at *cbca.gov/howto/rules/transportation.html#transportation.*

[78 FR 71529, Nov. 29, 2013, as amended at 87 FR 32327, May 31, 2022]
#### § 102-117.285 What are my choices if a TSP's performance is not satisfactory?

You may choose to place a TSP in temporary nonuse, suspension, or debarment if performance is unsatisfactory.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsFlight investigation of stall, spin and recovery characteristics of a low-wing, single-engine, T-tail light airplaneFlight tests were performed to investigate the stall, spin, and recovery characteristics of a four-place, low-wing, single-engine, T-tail, general aviation research airplane at an aft center-of-gravity position. Most stalls resulted in roll-offs. Spins were oscillatory in roll and pitch at 43 deg angle of attack; the magnitude of the oscillations was determined by aileron position. Power, flap deflection, and landing gear position did not affect the angle of attack to the spin. Antispin rudder followed by forward wheel with ailerons neutral produced the fastest and most consistent recoveries but the initial application of recovery controls did not always stop a spin.Document ID19850016937Acquisition SourceLegacy CDMSDocument TypeTechnical Publication (TP)AuthorsStough, H. P., III*(NASA Langley Research Center Hampton, VA, United States)*Dicarlo, D. J.*(NASA Langley Research Center Hampton, VA, United States)*Patton, J. M., Jr.*(NASA Langley Research Center Hampton, VA, United States)*Date AcquiredSeptember 5, 2013Publication DateMay 1, 1985Subject CategoryAircraft Design, Testing And PerformanceReport/Patent NumberNAS 1.60:2427L-15868NASA-TP-2427Accession Number85N25248Funding Number(s)PROJECT: RTOP 505-45-23Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType19850016937.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Exhibit 32.1

# CERTIFICATION PURSUANT
TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANESOXLEY ACT OF 2002

In connection with the Annual Report
of Silverstar Holdings, Ltd. (the Company) on Form 10-K for the year ended
June 30, 2004 as filed with the Securities and Exchange Commission on the date hereof (the
Report), I, Clive Kabatznik, Chief Executive Officer (Principal Executive
Officer) and Chief Financial Officer (Principal Financial Officer) of the Company,
certify, pursuant to 18 U.S.C. §1350, adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 that to my knowledge:

|(1) |  | The Report fully complies with the requirements of Section 13(a) or 15(d), as
               applicable, of the Securities Exchange Act of 1934; and
|--- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------

|(2) |  | The information contained in the Report fairly presents, in all material
               respects, the financial condition and results of operations of the Company at
               the dates and for the periods indicated.
|--- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | /s/ Clive Kabatznik                        
| | -------------------------------------------
| | Clive Kabatznik                            
| | Chief Executive Officer and                
| | Chief Financial Officer                    
| | (Principal Executive and Financial Officer)
| | Date: September 28, 2006                   

A signed original of this written
statement required by Section 906, or other document authenticating, acknowledging, or
otherwise adopting the signature that appears in typed form within the electronic version
of this written statement required by Section 906, has been provided to Silverstar
Holdings, Ltd. and will be retained by Silverstar Holdings, Ltd. and furnished to the
Securities and Exchange Commission or its staff upon request.
| Reference: | Purchase Agreement No. 3219 (the Purchase Agreement) between The Boeing Company (Boeing) and American Airlines, Inc. (Customer) relating to Model 787-923 aircraft (Aircraft) and 787-323 and 787-823 Substitute Aircraft (each Substitute Aircraft) |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

|   | Its                                           |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
0:22-cv-62054-WPD

Nov 4, 2022 s/ R. Bissainthe

Case 0:22-cv-62054-AHS Document 3 Entered on FLSD Docket 11/04/2022 Page 1 of 1
-cr-06240-WPD Document 25 Entered on FLSD Docket 09/19/2001 P
-cr-06240-WPD Document 25 Entered on FLSD Docket 09/19/2001 P
Case 1:00-cr-00807-FAM Document 78 Entered on FLSD Docket 06/08/2001 Page 1 of 1
EX-4.7





 Exhibit 4.7 

Equity Investment Agreement 
 Party A:
AnPac Bio-Medical Science Co., Ltd. 
 Party B: Chris Chang Yu    Identity document:
Passport    Identity document number: [    ] 
 Party A, namely AnPac
Bio-Medical Science Co., Ltd., is a company with the registered address at Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands (“AnPac”). AnPac is devoted to the
research and development and commercialization of its bio-medical technology. Its self-developed CDA detection technology platform has been applied to early cancer screening and detection. With research
studies on approximately 40,000 samples, the CDA technology has been proven to have high sensitivity and specificity rates. AnPac is at the moment speeding up the penetration of its CDA technology platform in China and the United States, and
accelerating its research and development and marketing work in these markets. 
 Party B is the founder, principal shareholder and chairman
of the board of Party A. Considering Party A’s development in various aspects and demand for capital, Party B decided to increase the capital of Party A in the second quarter of 2020 (the “Investment”). 

Pursuant to the result of negotiation between Party A and Party B (collectively, the “Parties”), the Parties agreed as
follows: 
 1. The market value of Party A shall be determined according to the most recent valuation of Party A for equity financing
purpose. The number of issued and outstanding shares of Party A shall be the number of shares issued and outstanding immediately after the most recent equity financing of Party A. 

2. Party B shall invest USD2.0 million (the “Investment Amount”) in Party A. 

3. Party B undertakes to complete the investment in Party A by the end of the second quarter of 2020. The Investment Amount shall be wired
into the account below or other account designated by Party A: 
 Transferee: AnPac Bio-Medical
Science Co., Ltd. 
 Bank: [    ] 

Account no.: [    ] 

Address: No. [    ] 

4. Party A undertakes that before any exit or sale by Party B of the shares he acquired of Party A through the investment, Party A shall not,
directly or indirectly through any other entity, engage in any business which competes with Party A’s business. 

  
 1 













 5. Party B undertakes that while being a shareholder of Party A’s, Party B will not
directly or indirectly engage in any business which competes with Party A’s business, and Party B undertakes to utilize his own resources to support Party A’s business development. 

6. Party A will procure the issuance of share certificates within two (2) months after the Investment Amount is wired in full by Party B
into the designated account. 
 7. Party B may sell the shares through Party A’s successful public listing of its shares or by share
transfers through acquisition agreements. 
 8. Any disputes between the Parties shall be heard and decided by the People’s Court of
Huangpu District in Shanghai. 
  

			
	Party A (Stamp):	  	Party B (Signature):
		
	/s/ AnPac Bio-Medical Science Co., Ltd.	  	/s/ Chris Chang Yu
		
	Date: August 11, 2019	  	Date: August 11, 2019


  
 2
I

106TH CONGRESS

2D SESSION H. R. 5434

To amend title XVIII of the Social Security Act to eliminate discriminatory

copayment rates for outpatient psychiatric services under the Medicare

Program.

IN THE HOUSE OF REPRESENTATIVES

OCTOBER 10, 2000

Mrs. ROUKEMA introduced the following bill; which was referred to the Committee on Commerce, and in addition to the Committee on Ways and

Means, for a period to be subsequently determined by the Speaker, in

each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to eliminate

discriminatory copayment rates for outpatient psychiatric

services under the Medicare Program.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘Medicare Mental Ill5 ness Nondiscrimination Act of 2000’’.
2

•HR 5434 IH

1 SEC. 2. ELIMINATION OF DISCRIMINATORY COPAYMENT

2 RATES FOR MEDICARE OUTPATIENT PSY3 CHIATRIC SERVICES.

4 Section 1833 of the Social Security Act (42 U.S.C.

5 1395l) is amended by striking subsection (c).

Æ